Employees: 65
Size SK Discovery (006120.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $866M, the 259th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩68,200 on 18 Nov 2026.
Performance Over six months the shares gained 25.1%, against -26.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 23.5% over the last twelve months (peer median +1.4%); the operating margin is 2.6% (peer median -0.8%).
Valuation It trades at 0.8× enterprise value to sales against a peer median of 5.8× (cheapest of 18).
Capital Return on invested capital runs 3.5 points below its cost of capital (5.0% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩12.4T | ₩10.2T | ₩9.04T | ₩8.94T | ₩8.72T |
| Revenue growth | — | +12% | +1% | +3% | — |
| Gross profit | ₩1.36T | ₩1.20T | ₩936B | ₩963B | ₩767B |
| EBITDA | ₩909B | ₩884B | ₩540B | ₩603B | ₩543B |
| Net income | ₩382B | ₩129B | ₩36.5B | ₩191B | ₩427B |
| Free cash flow | -₩353B | -₩143B | -₩774B | -₩393B | -₩532B |
| Capital expenditure | ₩834B | ₩843B | ₩833B | ₩971B | ₩625B |
| Total debt | ₩8.00T | ₩7.26T | ₩6.44T | ₩4.77T | ₩4.13T |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 006120.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.0% | -11.6% | 6th highest of 21 |
| 6-month return | +25.1% | -26.0% | highest of 19 |
| Distance from 52-week high | -6.6% | -43.7% | highest of 21 |
| Revenue growth (TTM) | +23.5% | +1.4% | 3rd highest of 19 |
| Operating margin | 2.6% | -0.8% | 9th highest of 19 |
| EV / Sales | 0.8× | 5.8× | cheapest of 18 |
| ROIC minus cost of capital | -3.5 pp | -2.3 pp | 7th lowest of 15 |
| EV / EBITDA | 11.0× | 8.8× | 3rd most expensive of 6 |
| Net debt / EBITDA | 4.6× | -0.9× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |